Annual Meeting and published in The New England Journal of Medicine. This latest approval positions Enhertu earlier in the treatment paradigm for HR-positive, HER2-low breast cancer and expands ...

The results of this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The New England Journal of Medicine. This latest approval positions ...

The trial’s findings were published in The New England Journal of Medicine. This development ... The company’s drug Enhertu received approval from the European Union for treating a specific ...

The trial’s findings were published in The New England Journal of Medicine. This development adds to AstraZeneca ... The company’s drug Enhertu received approval from the European Union for treating a ...

EU approves AstraZeneca’s Imfinzi-in combo with chemotherapy to treat patients with resectable non-small cell lung cancer ...

In the phase 3 ALINA study published recently in the New England Journal of Medicine, adjuvant Alecensa ... approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to treat adults with unresectable or metastatic hormone ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to treat a broader population of HER2-low breast cancer patients. The drug has ...